Mergers and Acquisitions Remain Key in Big Pharma's 2013 Playbook, an
Industrial Info News Alert
SUGAR LAND, TX -- (Marketwire) -- 01/28/13 -- Reported by Annette
Kreuger, Industrial Info Resources (Sugar Land, Texas) -- In the
absence of the avalanche of mega-industry mergers and acquisitions
(M&A) seen in previous years, many pundits have proclaimed the end of
that particular business tool as an essential component in Big
Pharma's playbook. While the numbers in 2012 were lower than in years
past in both quantity and value, it is clear that M&A plans remain a
key factor for the industry. With 2013 barely under way, there are
many rumors of new deals ahead.
Other companies featured: Pfizer Incorporated (NYSE:PFE), Merck
(NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), GlaxoSmithKline
(NYSE:GSK), Watson Pharmaceuticals Incorporated (NYSE:WPI), Allergan
Incorporated (NYSE:AGN), MAP Pharmaceuticals (NASDAQ:MAPP)
For details, view the entire article by subscribing to Industrial
Info's Premium Industry News at
or browse other breaking industrial news stories at
Industrial Info Resources (IIR), with global headquarters in Sugar
Land, Texas, and eight offices outside of North America, is the
leading provider of global market intelligence specializing in the
industrial process, heavy manufacturing and energy markets.
Industrial Info's quality-assurance philosophy, the Living Forward
Reporting Principle(TM), provides up-to-the-minute intelligence on
what's happening now, while constantly keeping track of future
opportunities. To contact an office in your area, visit the
www.industrialinfo.com "Contact Us" page.
Press spacebar to pause and continue. Press esc to stop.